Published by Coherent Market Insights
Posted on October 8, 2021
6 min readLast updated: January 30, 2026
The Castrate-resistant Prostate Cancer market is expected to grow significantly, reaching $16.4 billion by 2028, despite challenges posed by COVID-19.
The global Castrate-resistant Prostate Cancer market is expected to reach US$ 16.4 Billion by 2028 from US$ 9.5 Billion in 2020, at a CAGR of 8.2%. The base year considered for the study is 2020 and the forecast period 2021-2028.
Castration-resistant prostate cancer (CRPC) is a type of advanced prostate cancer that is resistant to testosterone-lowering treatments. Symptoms of mCRPC include: difficulty urinating, pain while passing urine, or blood in the urine, weight loss and shortness of breath. Hormonal therapies are used to treat CRPC such as abiraterone (Zytiga) with corticosteroids inhibit the chemical production of testosterone throughout the body. Zytiga is used in conjunction with prednisone, a powerful anti-inflammatory medication. Other treatments for CRPC include chemo and immunotherapies.
Market players are focused on raising awareness campaigns related to prostate cancer, which is expected to fuel growth of the global castrate-resistant prostate cancer market over the forecast period. For instance, on June 17, 2021, patient organization ZERO and Bayer AG, a global life sciences company, collaborated to launch ‘We’re Not Gonna Take It’, a national prostate cancer education program. The campaign encourages men to get screened for prostate cancer and to learn more about risk factors such as family history and elevated prostate-specific antigen (PSA) levels.
Request Sample Castrate-resistant Prostate Cancer market Report @
https://www.coherentmarketinsights.com/insight/request-sample/4529
The COVID-19 pandemic and lockdown in various countries across the globe have impacted the financial status of businesses across all sectors including private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry mainly due to strict lockdown in several regions. The COVID-19 pandemic has affected the economy of various regions across the globe in three main ways; 1) by directly affecting the production and demand; 2) by creating disruptions in distribution channels; and 3) through its financial impact on companies and financial markets.
Many countries such as Thailand, Indonesia, and Singapore are facing problems with regards to transportation and distribution of healthcare products. Delays and cancellations of cancer treatments, as well as other precautions taken to reduce the risk of exposure to the coronavirus (COVID-19), have created a massive backlog in oncology care and research. Thus, impact of the coronavirus (COVID-19) pandemic is expected to limit growth of the global castrate-resistant prostate cancer market during the forecast period.
For instance, according to the European Society for Medical Oncology (ESMO) Virtual Congress 2020, a study was conducted in which responses were gathered from oncology centers in 18 different countries in Europe. Overall, 60.9% of oncology centers’ clinical activity was reduced during the pandemic’s peak, while around two-thirds accounting for 64.2% cited under-treatment as a major concern, and 37% expected significant reductions in clinical trials by the end of 2020.
Ask for PDF sample Castrate-resistant Prostate Cancer market report @
https://www.coherentmarketinsights.com/insight/request-pdf/4529
The objectives of this study are as follows:
To define, describe, and forecast the global Castrate-resistant Prostate Cancer market by product & service, technique, design, application, end user, and region
To provide detailed information regarding the major factors influencing market growth (drivers, restraints, opportunities, and industry-specific challenges)
To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
To analyze market opportunities for stakeholders and provide details of the competitive landscape for the key players
To forecast the size of the market with respect to five regions: North America, Europe, Asia Pacific, and the Rest of the World
To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
To track and analyze competitive developments in the Castrate-resistant Prostate Cancer market, such as agreements, collaborations, acquisitions, product launches, expansions, and R&D activities
• Data regarding the industry share by every item fragment, alongside their reasonable worth, have been served in the report.
• We provide statistic information, strategic and analysis tool results to provide a sophisticated landscape and target key market players.
• Our report helps readers decipher the current and future constraints of the market and optimal business strategies to enhance market development.
• Our reports have been examined by professional experts of the industry, which makes them beneficial for the company to maximize their return on investment.
• The analysis acknowledges that the sector players & key drivers of both conflicts and growth assess the impact of limitations as well as the opportunities on the sector.
Buy This Complete A Business Report With Flat US $2000 Off @
https://www.coherentmarketinsights.com/promo/buynow/4529
Available Customizations
With the given market data, Coherent Market Insights offers customizations as per the company‘s specific needs.
The following customization options are available for this report.
This report segments the Castrate-resistant Prostate Cancer market into product & service, technique, design, application, end user, and region. Based on products & services, the market is segmented into test kits and testing services. In 2020, the test kits segment accounted for the largest share of the total market. The growing demand for Castrate-resistant Prostate Cancer in research as well as diagnostics to understand the genetic variability of chronic disorders is propelling the growth of this Castrate-resistant Prostate Cancer market segment.
Based on design, the Castrate-resistant Prostate Cancer market is segmented into predesigned and customized panels. The customized Castrate-resistant Prostate Cancer segment is expected grow at the highest CAGR during the forecast period. This growth is attributed to the evolving needs of the emerging therapeutic and diagnostic application sectors and the increasing number of clinical and preclinical research studies.
The Castrate-resistant Prostate Cancer market is fragmented with the presence of several small and big players. Prominent players in this market include Sanofi, Johnson & Johnson Services Inc., Pfizer Inc., Astellas Pharma Inc., Bayer AG, Bristol Myers Squibb, Merck Sharp & Dohme, Novartis International AG, Eli Lilly & Company, and AstraZeneca plc.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
The post Castrate-resistant Prostate Cancer Market to See Booming Develop Rapidly | Sanofi, Pfizer, Astellas Pharma, Bayer AG appeared first on Gatorledger.
The article discusses the growth and challenges of the Castrate-resistant Prostate Cancer market.
COVID-19 has caused disruptions in cancer treatment and clinical trials, affecting market growth.
Key treatments include hormonal therapies like Zytiga and prednisone, as well as chemo and immunotherapies.
Explore more articles in the Research Reports category
